Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Soleno Therapeutics (NASDAQ: SLNO) announced that Anish Bhatnagar, M.D., Chief Executive Officer will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025 at 9:00 AM ET.
A live audio webcast and replay will be available in the Investors section of the company website at www.soleno.life.
Positive
- None.
Negative
- None.
News Market Reaction – SLNO
In the Nov 24 session, SLNO gained 1.77%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
